A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Quetiapine-D8 | CAS 1185247-11-3 - Request Quote

Picture of Quetiapine-D8

Quetiapine-D8

SZ CAT No:SZ-Q001D05
CAS No
1185247-11-3
Mol.F.
C21H17D8N3O2S
Mol.Wt.
391.6
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Quetiapine-D8 is chemically 2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl-2,2,3,3,5,5,6,6-d8)ethoxy)ethan-1-ol. Quetiapine-D8 is supplied with detailed characterization data compliant with regulatory guideline. Quetiapine-D8 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Quetiapine.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

Buy 1185247-11-3

Purchase 1185247-11-3

Order 1185247-11-3

Enquire 1185247-11-3

price of 1185247-11-3

1185247-11-3 Supplier

1185247-11-3 Manufacturer

1185247-11-3 Exporter

buy high quality Quetiapine-D8

Purchase Quetiapine-D8

Quetiapine-D8 suppliers

Quetiapine-D8 manufacturers

Quetiapine-D8 price

Order Quetiapine-D8

Enquire Quetiapine-D8

Quetiapine-D8 cost

Quetiapine-D8 Supplier

Quetiapine-D8 Distributor

Quetiapine-D8 for Method Validation

Quetiapine Reference Standard

Quetiapine-D8 for ANDA Filing

Quetiapine-D8 for Forced Degradation Studies

Quetiapine-D8 Identification Standards

Quetiapine-D8 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,